RE:RE:RE:RE:RE:RE:Back to 0,07 It doesn't look like you are very good at DD when it came to V.CLAS The outfit is likely out of money as their cash balance was negative as of September/2020 . Pharma outfits are notoriously good at burning cash . Curious what the eff are you doing on this board anyways ?
Kalytera is a clinical-stage specialty pharmaceutical company developing a portfolio of pharmaceutical products. Kalytera currently has no product candidate that has received regulatory approval. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet generated revenues and has incurred losses from operations since its inception. As of September 30, 2020, the Company has a working capital deficiency of $6,122 and an accumulated deficit of $54,353. At December 31, 2019, the Company failed to repay the 2017 Convertible Debentures, and as such, as of December 31, 2019 is in Default Event (see also Note 8a). As for the Company's obligations under the promissory note held by the former Talent shareholders, following the balance sheet date the Company did not pay the amount due on the extended maturity date and the Company received formal notice of default from the representative of the Former Shareholders (see also Note 1b and 1c). Continuation as a going concern is dependent upon obtaining additional capital. The Company will require a substantial amount of additional funds to complete the development of its products, to build a sales and marketing organization, and to fund additional losses, which the Company expects to incur over the next few years. The management of the Company intends to seek additional funding through private placements and public offerings, which will be utilized to fund product development and continue operations.